

# Andras Inotai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2712312/publications.pdf>

Version: 2024-02-01

31  
papers

827  
citations

623734

14  
h-index

501196

28  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1218  
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors Associated with Medication Adherence in Patients with Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 2011, 82, 328-334.	2.6	117
2	Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review. <i>Eating and Weight Disorders</i> , 2015, 20, 1-12.	2.5	110
3	Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 195-204.	1.4	92
4	Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. <i>Frontiers in Pharmacology</i> , 2018, 8, 942.	3.5	70
5	Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 183-190.	1.9	55
6	Relationship Between Medication Adherence and Health-Related Quality of Life in Subjects With COPD: A Systematic Review. <i>Respiratory Care</i> , 2015, 60, 297-303.	1.6	47
7	Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 915-926.	3.1	38
8	Need for Multicriteria Evaluation of Generic Drug Policies. <i>Value in Health</i> , 2015, 18, 346-351.	0.3	35
9	Guidance toward the implementation of multicriteria decision analysis framework in developing countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 585-592.	1.4	24
10	Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia. <i>BMC Health Services Research</i> , 2018, 18, 1003.	2.2	23
11	Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. <i>BioMed Research International</i> , 2018, 1-9.	1.9	23
12	Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology. <i>BMC Health Services Research</i> , 2012, 12, 332.	2.2	22
13	Modelling the burden of disease associated malnutrition. <i>E-SPEN Journal</i> , 2012, 7, e196-e204.	0.5	19
14	Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. <i>Rheumatology International</i> , 2012, 32, 963-969.	3.0	17
15	Drug Policy in Hungary. <i>Value in Health Regional Issues</i> , 2017, 13, 16-22.	1.2	14
16	Overview on Patient Centricity in Cancer Care. <i>Frontiers in Pharmacology</i> , 2017, 8, 698.	3.5	13
17	Benefits of investment into modern medicines in Central-Eastern European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 71-79.	1.4	11
18	Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 105-113.	1.4	11

#	ARTICLE	IF	CITATIONS
19	How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? â€” the good, the bad, and the ugly ways. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 627-632.	1.4	10
20	Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 653-659.	1.4	8
21	Potential Cost-Savings From the Use of the Biosimilars in Slovakia. Frontiers in Public Health, 2020, 8, 431.	2.7	8
22	Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries. Frontiers in Pharmacology, 2020, 11, 845.	3.5	8
23	Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis. International Journal of Technology Assessment in Health Care, 2009, 25, 190-195.	0.5	7
24	Barriers and facilitators of exploiting the potential of value-added medicines. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 229-236.	1.4	7
25	Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings. Cost Effectiveness and Resource Allocation, 2021, 19, 57.	1.5	7
26	Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary. Value in Health Regional Issues, 2015, 7, 1-8.	1.2	6
27	Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives. Cost Effectiveness and Resource Allocation, 2021, 19, 42.	1.5	5
28	The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia. Frontiers in Pharmacology, 2021, 12, 795002.	3.5	5
29	Proposal for capturing patient experience through extended value frameworks of health technologies. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 936-947.	0.9	4
30	The impact of implemented regulations on biosimilars in Slovakia. Health Policy and Technology, 2019, 8, 408-413.	2.5	3
31	Determinants of NSAID choice in rheumatoid arthritis--a drug utilization study. Acta Poloniae Pharmaceutica, 2012, 69, 773-7.	0.1	1